Upper gastrointestinal bleeding associated with the use of NSAIDs -: Newer versus older agents

被引:177
作者
Laporte, JR
Ibáñez, L
Vidal, X
Vendrell, L
Leone, R
机构
[1] Univ Autonoma Barcelona, Hosp Univ Vall Hebron, Fdn Inst Catala Farmacol, Dept Pharmacol Therapeut & Toxicol, Barcelona 08035, Spain
[2] Hosp Univ Vall Hebron, Clin Pharmacol Serv, Catalonia, Spain
[3] Univ Verona, Serv Farmacol Med, I-37100 Verona, Italy
关键词
D O I
10.2165/00002018-200427060-00005
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Aim: The relative gastrointestinal toxicity of NSAIDs in normal clinical practice is unknown. The aim of this study was to estimate the risk of upper gastrointestinal bleeding associated with NSAIDs and analgesics, with special emphasis on those agents that have been introduced in recent years. Design: Multicentre case-control study. Patients: All incident community cases of upper gastrointestinal bleeding from a gastric or duodenal lesion in patients aged >18 years of age (4309 cases). After secondary exclusions, 2813 cases and 7193 matched controls were included in the analysis. Setting: Eighteen hospitals in Spain and Italy with a total study experience of 10 734 897 person-years. Main Outcome Measure: Odds ratios of upper gastrointestinal bleeding for each drug, with adjustment for potential confounders. For each individual drug the reference category was defined as those not exposed to the drug. Results: The incidence of upper gastrointestinal bleeding was 401.4 per million inhabitants aged >18 years. Thirty-eight percent of cases were attributable to NSAIDs. Individual risks for each NSAID were dose dependent. Ketorolac was associated with the highest risk estimate (24.7; 95% CI 8.0, 77.0). For newer NSAIDs, the risks were as follows: aceclofenac 1.4 (95% CI 0.6, 3.3), celecoxib 0.3 (95% CI 0.03, 4.1), dexketoprofen 4.9 (95% CI 1.7, 13.9), meloxicam 5.7 (95% CI 2.2, 15.0), nimesulide 3.2 (95% CI 1.9, 5.6) and rofecoxib 7.2 (95% CI 2.3, 23.0). The risk was significantly increased in patients with a history of peptic ulcer and/or upper gastrointestinal bleeding, and in those taking antiplatelet drugs. Conclusions: NSAID-induced upper gastrointestinal bleeding is a common cause of hospital admission. Apart from the patient's history of peptic ulcer, its risk depends on the particular drug and its dose, and on concomitant treatments. Our results do not confirm that greater selectivity for COX-2 confers less risk of upper gastrointestinal bleeding.
引用
收藏
页码:411 / 420
页数:10
相关论文
共 23 条
[1]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[2]   ESTIMATING THE POPULATION ATTRIBUTABLE RISK FOR MULTIPLE RISK-FACTORS USING CASE-CONTROL DATA [J].
BRUZZI, P ;
GREEN, SB ;
BYAR, DP ;
BRINTON, LA ;
SCHAIRER, C .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1985, 122 (05) :904-913
[3]  
Feldman M, 2000, ANN INTERN MED, V132, P134, DOI 10.7326/0003-4819-132-2-200001180-00008
[4]   VARIABILITY IN THE RISK OF MAJOR GASTROINTESTINAL COMPLICATIONS FROM NONASPIRIN NONSTEROIDAL ANTIINFLAMMATORY DRUGS [J].
HENRY, D ;
DOBSON, A ;
TURNER, C .
GASTROENTEROLOGY, 1993, 105 (04) :1078-1088
[5]   Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis [J].
Henry, D ;
Lim, LLY ;
Rodriguez, LAG ;
Gutthann, SP ;
Carson, JL ;
Griffin, M ;
Savage, R ;
Logan, R ;
Moride, Y ;
Hawkey, C ;
Hill, S ;
Fries, JT .
BRITISH MEDICAL JOURNAL, 1996, 312 (7046) :1563-1566
[6]   Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation -: An overview of epidemiologic studies published in the 1990s [J].
Hernández-Díaz, S ;
Rodríguez, LAG .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (14) :2093-2099
[7]   NONSTEROIDAL ANTIINFLAMMATORY DRUG-USE IN RELATION TO MAJOR UPPER GASTROINTESTINAL-BLEEDING [J].
KAUFMAN, DW ;
KELLY, JP ;
SHEEHAN, JE ;
LASZLO, A ;
WIHOLM, BE ;
ALFREDSSON, L ;
KOFF, RS ;
SHAPIRO, S .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (04) :485-494
[8]   Cyclooxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibitors [J].
Kulkarni, SK ;
Jain, NK ;
Singh, A .
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2000, 22 (05) :291-298
[9]   Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding [J].
Lanas, A ;
Bajador, E ;
Serrano, P ;
Fuentes, J ;
Carreno, S ;
Guardia, J ;
Sanz, M ;
Montoro, M ;
Sainz, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (12) :834-839
[10]   RISKS OF BLEEDING PEPTIC-ULCER ASSOCIATED WITH INDIVIDUAL NONSTEROIDAL ANTIINFLAMMATORY DRUGS [J].
LANGMAN, MJS ;
WEIL, J ;
WAINWRIGHT, P ;
LAWSON, DH ;
RAWLINS, MD ;
LOGAN, RFA ;
MURPHY, M ;
VESSEY, MP ;
COLINJONES, DG .
LANCET, 1994, 343 (8905) :1075-1078